Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Limited (NASDAQ: BNR) is a cancer diagnostics company focused on applying next generation sequencing (NGS) technology to precision oncology. The BNR news stream features company announcements on therapy selection testing, early cancer detection programs, pharmaceutical collaborations and financial performance.
In its press releases, Burning Rock regularly reports quarterly and annual financial results, with details on revenues from its central laboratory business, in-hospital business and pharma research and development services. These updates often include commentary on gross margins, operating expenses, and the mix of revenue from Mainland China and overseas customers.
News about Burning Rock also covers scientific and clinical milestones. The company highlights study results on circulating tumor DNA (ctDNA), minimal residual disease (MRD) monitoring, and multi-cancer early detection, presented at major conferences and in journals. It reports on the progress of products such as OncoScreen™ Plus, the CanCatch® Custom MRD assay, and multi-omics early detection tests that have advanced into clinical validation.
Another key theme in BNR news is companion diagnostics and pharmaceutical partnerships. Burning Rock has announced CDx collaborations, regulatory approvals such as the OncoGuide™ OncoScreen™ Plus CDx System in Japan, and an NMPA-approved NGS-based CDx for EGFR exon 20 insertion mutation in lung cancer. Corporate governance items, including annual general meeting results and auditor appointments, also appear in the company’s news flow.
Investors and healthcare professionals can use this news page to follow Burning Rock’s disclosures on its precision oncology platform, business segment trends, regulatory developments and scientific achievements related to BNR stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) announced plans to release its unaudited financial results for Q1 2023 on May 30, 2023, before U.S. market opens. Management will hold a conference call at 8:00 a.m. ET on the same day. The company anticipates moderate revenue growth year-over-year, driven by a strong rebound in March, reversing previous declines in January-February. March 2023 total test volumes increased by approximately 29% year-over-year, attributed mainly to growth in the in-hospital channel. Investors can register for the call and access a live webcast on the company’s investor relations website.
Burning Rock Biotech Limited (NASDAQ: BNR), focused on next-generation sequencing technology for precision oncology, filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. SEC on April 21, 2023. The report is accessible on both the SEC website and the company's own site.
Burning Rock's business segments include NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has advanced to the clinical validation phase. The company's mission remains centered on enhancing cancer care through scientific innovation.
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for the fourth quarter and full year 2022. The company recorded revenues of RMB142.2 million (US$20.6 million) for Q4 2022, a 3.5% decrease compared to Q4 2021, mainly due to COVID-19 impacts. For full-year 2022, revenues rose 10.9% to RMB563.2 million (US$81.7 million). The net loss for Q4 2022 was RMB216.2 million (US$31.4 million), improved from RMB251.1 million in Q4 2021. The company achieved a significant milestone with its Early Detection OverCTM test receiving Breakthrough Device Designation from the FDA. 2023 revenue guidance suggests an expected growth of approximately 20% over 2022.
Burning Rock Biotech Limited (NASDAQ: BNR) has announced plans to release its unaudited financial results for the fourth quarter and full year 2022 prior to the U.S. market opening on March 28, 2023. Following the results, management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) to discuss the financial outcomes. The company focuses on next generation sequencing (NGS) technology in precision oncology, which includes therapy selection testing for late-stage cancer patients and early cancer detection now in clinical validation. Investors can pre-register for the conference call through the provided link.